|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-6-6
|
|
pubmed:abstractText |
To evaluate the toxicity and efficacy of a newly developed topoisomerase I inhibitor, CKD-602 in second-line therapy of ovarian cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1095-6859
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
109
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
359-63
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18405948-Adult,
pubmed-meshheading:18405948-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:18405948-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18405948-Camptothecin,
pubmed-meshheading:18405948-Drug Administration Schedule,
pubmed-meshheading:18405948-Drug Resistance, Neoplasm,
pubmed-meshheading:18405948-Enzyme Inhibitors,
pubmed-meshheading:18405948-Female,
pubmed-meshheading:18405948-Humans,
pubmed-meshheading:18405948-Middle Aged,
pubmed-meshheading:18405948-Neoplasm Recurrence, Local,
pubmed-meshheading:18405948-Organoplatinum Compounds,
pubmed-meshheading:18405948-Ovarian Neoplasms,
pubmed-meshheading:18405948-Topoisomerase I Inhibitors
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul 110-744, Korea.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
